Vericel Stock (NASDAQ:VCEL), Trade Ideas

Vericel

Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company, specialized in various therapies for sports medicine and severe burn care markets. It markets two cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane) and Epicel (cultured epidermal autografts). The company operates in one reportable segment: the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases.

Equities

News

Contracts

Small Cap

Markets

General

MDWD

VCEL

Biopharmaceutical company MediWound Ltd (NASDAQ: MDWD) reported that the U.S.

Innovative Burn Care: MediWound Bags Additional DoD Grant For NexoBrid Development

Short Ideas

Health Care

Trading Ideas

J Capital Research has released a short idea report on Vericel Corporation (NASDAQ: 

Vericel&#39;s Short Report: Deep Dive Into Knee-Repair Focused Company&#39;s 27 Years of Losses

As America Grapples With A Deadly Opioid Epidemic, BioRestorative Therapies Is Looking To Treat Chronic Pain Without The Need For Class-A Drugs

Biotech

Penny Stocks

ABBV

BRTX

LGVN

MESO

Chronic back pain is a significant issue in the United States, affecting millions of individuals annually. According to experts, up to 80% of the population will experience back pain at some point.

Vericel Corp

Piper Sandler analyst Kashy Harrison reiterates Enphase Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENPH#NASDAQ">ENPH</a>) with a Neutral and lowers the price target from $113 to $111.

Price Target

Reiteration

Analyst Ratings

ENPH

Piper Sandler Reiterates Neutral on Enphase Energy, Lowers Price Target to $111

International Business Machines Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBM#NYSE">IBM</a>) is expected to release earnings results for its first quarter, after the <a href="https://www.benzinga.com/quote/IBM/earnings">closing bell on April 24, 2024</a>.
Analysts expect the Armonk, New York-based company to report quarterly earnings at $1.60 per share, up from $1.36 per share in the year-ago quarter. IBM is projected to report quarterly revenue of $14.55 billion, compared to $14.25 billion in the year-earlier period, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On Jan. 30, IBM's board of directors declared a regular quarterly cash dividend of $1.66 per common share.
IBM shares rose 0.2% to close at $182.19 on Tuesday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/IBM/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul>
<li>Jefferies analyst Brent Thill maintained a Hold rating and cut the price target from $215 to $210 on April 23, 2024. This analyst has an accuracy rate of 78%.</li>
<li>UBS analyst David Vogt maintained a Sell rating and raised the price target from $125 to $130 on April 22, 2024. This analyst has an accuracy rate of 76%.</li>
<li>B of A Securities analyst Wamsi Mohan maintained a Buy rating and increased the price target from $200 to $220 on March 14, 2024. This analyst has an accuracy rate of 75%.</li>
<li>BMO Capital analyst Keith Bachman maintained a Market Perform rating and boosted the price target from $155 to $210 on Jan. 25, 2024. This analyst has an accuracy rate of 78%.</li>
<li>Evercore ISI Group analyst Amit Daryanani upgraded the stock from In-Line to Outperform and increased the price target from $165 to $200 on Jan. 19, 2024. This analyst has an accuracy rate of 73%.</li>
</ul>
Read This Next: <a href="https://www.benzinga.com/news/earnings/24/04/38396305/tesla-boeing-and-3-stocks-to-watch-heading-into-wednesday">Tesla, Boeing And 3 Stocks To Watch Heading Into Wednesday</a>

Earnings

IBM Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

- Reuters Citing Annual Shareholders Meeting

Management

ASML

ASML Names Christophe Fouquet As Company's New CEO

The generational divide in the housing market has taken center stage as a TikTok user's rant draws attention to the affordability struggles faced by millennials and Gen Z.&nbsp;
This reaction follows a baby boomer's admission of purchasing a home for $37,000 in 1980 — a figure roughly equivalent to $148,000 today when adjusted for inflation. 
"They still point the finger at us for not getting out of our parents' basement — ‘You guys are just lazy,'" the TikToker said, encapsulating the disdain younger generations feel when unjustly branded by some baby boomers as indolent, despite an economic landscape that has shifted beneath their feet.
Don't Miss:
<ul>
<li>Investing in real estate just got a whole lot simpler. This <a href="https://www.benzinga.com/go/bezos-landlord">Jeff Bezos-backed startup will allow you to become a landlord</a> in just 10 minutes, and you only need $100.</li>
</ul>
In an ironic twist, a Redfin survey has revealed that a substantial portion of boomers would not be able to afford their homes in the current climate, where home values have surged.&nbsp;
Over the past decade, home values have doubled, with a nearly 50% increase in the last five years, pushing the cost of homeownership to record highs.
The survey posed a critical question to homeowners: Could they afford a home like theirs in their neighborhood if they were to buy it today? Approximately 40% of respondents answered they probably or definitely could not afford it. This sentiment was particularly strong among baby boomers, with 45% stating they couldn't afford a home in their current neighborhood under today's conditions.
Trending
<ul>
<li>Want To Grow Your Wealth Passively? Unlock Real Wealth with <a href="https://www.benzinga.com/money/cityfunds-yield">Cityfunds&#8217; Exclusive 8% Yield Fund</a>.</li>
</ul>
"Americans who already own homes benefit from rising values," Redfin senior economist Elijah de la Campa said. "However, this price appreciation makes the prospect of buying a new home daunting or even impossible for many who want to move."
While baby boomers may benefit from the appreciation of their properties, the same rising prices and spiked mortgage rates create barriers for newer entrants into the housing market. This situation contributes to a phenomenon known as the "mortgage-rate lock-in effect," where current homeowners are disincentivized to sell because of unfavorable mortgage rate comparisons.
While baby boomers might reminisce about the good old days when high interest rates were the main obstacle, today&#8217;s generation faces a more complex array of challenges: inflated property prices, a competitive market with low inventory and a cost of living that has risen disproportionately to wage growth.
The very factors that have allowed baby boomers to accumulate substantial home equity — soaring property values and historically low interest rates for decades — are now pricing younger generations out of the market. This paradox highlights the complexities of the housing crisis, where solutions will require addressing systemic issues around supply, costs and equity.
Read Next:
<ul>
<li>Want to Create a Passive Income Stream? <a href="https://www.benzinga.com/go/grow-wealth-passively">These High-Yield Real Estate Notes Might Be Your Holy Grail</a></li>
</ul>

Real Estate

Baby Boomers Call Gen Z And Millennials 'Lazy' For Living At Home, Yet Survey Shows Nearly 50% Couldn't Afford To Buy Their Homes Today

<a href="https://www.globenewswire.com/Tracker?data=hPvjTEXyxU-oT8onb4GE6yoLYP643J2tkQr15ddY0qIl3oT5KEu7o0ZLvtAEEGhA5xwQZjkGoTGCmekeXoc91ZRqMZhgoZCRAg1avFBh0w-HngxAGlquZroZbcigR1Uf">Cullinan Therapeutics, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGEM#NASDAQ">CGEM</a>), a biopharmaceutical company focused on modality-agnostic targeted therapies, today announced that clinical data from its Phase 1 trial of CLN-619 in patients with advanced solid tumors will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago from May 31-June 4, 2024. The data will include first results from the dose escalation cohort of CLN-619 in combination with checkpoint inhibitor pembrolizumab and updated results from the monotherapy dose escalation cohort in patients with advanced solid tumors. &nbsp;
"We are pleased to present our initial clinical findings for CLN-619 plus pembrolizumab in patients with solid tumors at ASCO 2024, along with updated results from our monotherapy dose escalation study. CLN-619 is a novel, potential first-in-class antibody that binds to MICA and MICB stress-induced ligands that engage the activating receptor NKG2D, present on both innate and adaptive immune cells. CLN-619 exerts its effects through multiple mechanisms, providing an opportunity to combine CLN-619 with immunotherapies that target potentially synergistic immune activation pathways, such as checkpoint inhibitors," said Jeffrey Jones, MD, MPH, MBA, Chief Medical Officer, Cullinan Therapeutics.
The details of the presentation include: &nbsp;
Poster Title:&nbsp;CLN-619 (anti-MICA/B antibody) alone and in combination with pembrolizumab for advanced solid tumors: Updated results of a Ph1 study &nbsp;
Author:&nbsp;Dr. Ignacio Melero, et al. &nbsp;
Poster Number: 2588 &nbsp;
Session:&nbsp;Developmental Therapeutics—Immunotherapy &nbsp;
Session Date and Time:&nbsp;June 1, 2024, 9:00 AM-12:00 PM Central Time
About CLN-619&nbsp; &nbsp;
CLN-619 is a potential first-in-class humanized IgG1 monoclonal antibody that binds to the stress induced ligands MICA and MICB, which are expressed on a wide variety of solid tumors and hematologic malignancies. Engagement of MICA/B by the activating receptor NKG2D, present on both cytotoxic innate and adaptive immune cells, results in target cell lysis. However, tumor cells can shed MICA/B via proteases they release into the tumor microenvironment, resulting in evasion of immune-mediated destruction. CLN-619 functions by restoring MICA/B expression on the surface of tumor cells to reinvigorate NKG2D-mediated immune activation, and by inducing antibody-dependent cellular toxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP), together promoting anti-tumor activity via multiple immune-mediated mechanisms. CLN-619 is being studied in an ongoing Phase 1 clinical trial (<a href="https://www.globenewswire.com/Tracker?data=-viKWMyCrcGEgeyEndGKWxkz5S-qtBs6wR3rdBf0k_GRMhg4uc__vP7YRSoXqSTFK4bMYDX9Rml0C-84cOM74Nyhqpb9zyyCD1MOzk9hFv2s402wPG4nhjExRU5Psbcc">NCT05117476</a>) both as a monotherapy and in combination with pembrolizumab. The study design allows dose level extensions as well as expansion in tumor-specific cohorts. CLN-619 will also be studied in a Phase 1 clinical trial <a href="https://www.globenewswire.com/Tracker?data=PvPgUcn-3MLOx6fhN3h35ZMxYO7BT9bIEuSHG13XXeQBc0HDIz0n_euWJ9C_qOi7Ig71exBtpKH01PYxbiD_8-tD5HMBa5X5USR760J1prjDBUTPhcdTyay6YcOnsN21">(NCT06381141)</a>&nbsp;in patients with relapsed/refractory multiple myeloma.

CGEM

Cullinan Therapeutics To Present Clinical Data From Phase 1 Study Evaluating Novel Anti-MICA/B Antibody, CLN-619, As Monotherapy And In Combination With A Checkpoint Inhibitor In Patients With Advanced Solid Tumors At ASCO 2024

Wednesday,&nbsp;Humana Inc&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) posted first-quarter adjusted EPS of $7.23, down from $9.38 a year ago, beating&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">the consensus of $6.12</a>.
The company reported revenues of 29.33 billion, up from $25.65 billion, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/04/b38398976/humana-reports-first-quarter-2024-financial-results-affirms-full-year-adjusted-2024-financial-guid" rel="noreferrer noopener">consensus of $28.47 billion</a>.
The revenues increased on higher per-member Medicare premiums and individual and group Medicare Advantage membership growth.
Humana&#8217;s stock has suffered after the&nbsp;company reported a surprising fourth-quarter loss&nbsp;and higher-than-expected medical costs from its Medicare Advantage business. Wednesday&#8217;s report was more positive.
Humana&nbsp;<a target="_blank" href="https://humana.gcs-web.com/static-files/b4f78b72-cce0-4003-9608-49edca0059d2" rel="noreferrer noopener">ended</a>&nbsp;the first quarter with 6.1 million in Medicare Advantage membership, up from 5.67 million in the first quarter of 2023.&nbsp;
In&nbsp;<a target="_blank" href="https://humana.gcs-web.com/static-files/4a3a2261-3d15-4997-8abc-cec1ed05876d" rel="noreferrer noopener">prepared remarks</a>, the management said the first quarter benefit ratio of 88.9% is in line with expectations as we have taken a more conservative approach to quarter-end reserving considering the Change Healthcare disruption, although&nbsp;certain&nbsp;key&nbsp;individual Medicare Advantage (MA) early indicators are&nbsp;largely&nbsp;in line to slightly positive expectations.
Humana boasted 16.17 million medical members at the end of the first quarter.
Guidance:&nbsp;Based on its performance, the company reaffirmed its 2024 adjusted earnings guidance of $16 per share versus the consensus of $16.36.&nbsp;
It is also anticipating a benefits ratio of 90% amid a spike in utilization in the Medicare Advantage (MA) program that dragged its&nbsp;<a target="_blank" href="https://www.benzinga.com/news/earnings/24/01/36675703/healthcare-insurance-giant-humana-stock-hits-52-week-low-today-heres-why" rel="noreferrer noopener">finances in the fourth quarter</a>.
Humana said it raised its individual Medicare Advantage annual membership growth by 50,000&nbsp;to anticipate an&nbsp;annual&nbsp;growth&nbsp;of approximately 150,000, or 2.8%.
Also Read:&nbsp;<a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38255526/see-how-floridas-much-awaited-medicaid-re-procurement-awards-impact-centene-humana-" rel="noreferrer noopener">See&nbsp;How Florida&#8217;s Much Awaited Medicaid Re-Procurement Awards Impact Centene, Humana, Molina</a>.
Price Action: HUM shares are down 3.68% at $315.86 at the last check Wednesday. The stock was up after earnings by as much as 3.75% in the premarket session.
Photo via Wikimedia Commons

Guidance

Movers

Humana Boosts Medicare Advantage Membership 2024 Forecast As Q1 Earnings Performance Exceeds Expectations

Snap Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNAP#NYSE">SNAP</a>) shares got a lift in premarket trading Wednesday before pulling back and turning negative after the open. Here&#8217;s a look at <a href="https://www.benzinga.com/news/24/04/38394855/biden-set-to-sign-tiktok-ban-into-law-after-senate-passes-bill-supported-by-gop-democrats">what&#8217;s going on</a>.
What To Know: Snap shares got a boost early Wednesday after Congress passed a bill to ban or force a sale of popular social media platform TikTok, per several <a href="https://www.benzinga.com/news/24/04/38394855/biden-set-to-sign-tiktok-ban-into-law-after-senate-passes-bill-supported-by-gop-democrats">reports</a>. 
The U.S. Senate approved the bill 79 to 18 as part of an aid package for Israel, Ukraine and Taiwan. The proposal is being sent to President Joe Biden's desk, and is expected to be signed this week.
Once signed, parent company ByteDance will have approximately nine months to sell TikTok. If the company fails to divest the popular app within that time, it will face a national ban. The lawmakers pushing to implement restrictions on TikTok have cited concerns that ByteDance ownership may allow the Chinese government to access American user data.
Snap shares may also be experiencing increased volatility ahead of earnings. The company is scheduled to report <a href="https://www.benzinga.com/calendars/earnings">financial results</a> for the first quarter after the market close on Thursday. Analysts are calling for an earnings loss of 5 cents per share on revenue of $1.119 billion, according to estimates from <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Check This Out: <a href="https://www.benzinga.com/markets/equities/24/04/38397484/gop-senator-who-owns-meta-stock-denies-conflict-of-interest-ahead-of-tiktok-ban-vote-i-am-not-fi">GOP Senator Who Owns Meta Stock Denies Conflict of Interest Ahead Of TikTok Ban Vote: &#8216;I Am Not Fighting Against A Company&#8217;</a>
<h2 class="wp-block-heading">Is SNAP A Good Stock To Buy?</h2>
An investor can make a few decisions when deciding whether a stock is a good buy. In addition to valuation metrics and price action which you can find on Benzinga's quote pages &#8211; like <a href='https://www.benzinga.com/quote/SNAP'>Snap</a>&#8216;s page for example &#8211; there are factors like whether or not a company pays a dividend or buys a large portion of its stock each quarter.
These are known as capital allocation programs. Snap does not pay a dividend, but obviously has a few ways it can return value to shareholders. Feel free to search Benzinga's <a href="https://www.benzinga.com/calendars/dividends">dividend calendar</a> for the next company that is due to pay a dividend and determine what kind of yield you can earn for holding a share of the company.
Buyback programs are different and highly variable. A company can approve a buyback program and purchase shares as it sees fit over the course of time in which the buyback was authorized. Looking through the latest news on <a href="https://www.benzinga.com/quote/SNAP">Snap</a> will often yield whether or not the company has approved a buyback program recently. Buyback programs usually serve as a support for share prices, serving as a backstop for demand.
SNAP Price Action: Snap shares were down 1.84% at $11.18 at the time of writing, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: courtesy of Snap.

SNAP

What's Going On With Snap Stock Today?

W.W. Grainger, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GWW#NYSE">GWW</a>) announced today that its board of directors approved a quarterly cash dividend of $2.05 per share, an increase of 10% from the most recent company dividend. The dividend is payable on June 1, 2024, to shareholders of record on May 13, 2024.
In addition, the board approved the repurchase of up to 5 million shares of the company's outstanding common stock, replacing the company's existing repurchase authorization. The new repurchase authorization has no expiration date. As of December 31, 2023, the company had approximately 49.3 million shares of common stock outstanding.
"2024 is on track to be our 53rd consecutive year of increased dividends, upholding Grainger's long-standing commitment to our shareholders. This increase, together with our updated share repurchase authorization, reinforces our ability to continue investing in the business while also returning excess cash to shareholders," said D.G. Macpherson, Grainger Chairman and CEO.

Dividends

Buybacks

Grainger Increases Quarterly Dividend By 10% From $1.86 To $2.05 Per Share; Refreshes Share Repurchase Authorization Of Up To 5M Shares Of The Co's Outstanding Common Stock, Replacing The Company's Existing Repurchase Authorization

Macro Economic Events

Economics

TSLA

Benzinga Morning Update: Tesla Surges On Earnings, Texas Instruments Lifts Chip Stocks Higher

<a href="https://www.baesystems.com/en/article/bae-systems-to-collaborate-with-cummins-on-transit-bus-hybrid-drivetrain-for-2027-and-beyond#:~:text=2027%20and%20beyond-,BAE%20Systems%20to%20collaborate%20with%20Cummins%20on%20transit,drivetrain%20for%202027%20and%20beyond&amp;text=BAE%20Systems%20and%20Cummins%20Inc,targeted%20for%20launch%20in%202027.">https://www.baesystems.com/en/article/bae-systems-to-collaborate-with-cummins-on-transit-bus-hybrid-drivetrain-for-2027-and-beyond#:~:text=2027%20and%20beyond-,BAE%20Systems%20to%20collaborate%20with%20Cummins%20on%20transit,drivetrain%20for%202027%20and%20beyond&amp;text=BAE%20Systems%20and%20Cummins%20Inc,targeted%20for%20launch%20in%202027.</a>
&nbsp;
Hybrid electric solution will continue to provide transit agencies with proven, cost-effective technology that reduces fuel use and emissions
BAE Systems and Cummins Inc. have announced plans to collaborate on the integration and certification of a B hybrid-compatible diesel engine and hybrid electric drivetrain for the transit market, targeted for launch in 2027. The hybrid electric solution will continue to provide transit agencies with a proven and cost-effective technology that reduces fuel use and emissions.
In this effort, BAE Systems will supply its <a href="https://www.baesystems.com/en/productfamily/electric-and-hybrid-solutions">electric drive</a> hardware to interface with the engine and form a full hybrid electric drivetrain, as well as provide engineering support and system integration expertise.
"Hybrid electric systems will remain an important technology for the bus market for years to come," said Rob Dykema, director of North American Transit Accounts for Power &amp; Propulsion Solutions at BAE Systems. "BAE Systems and Cummins have enjoyed many years of successful collaboration delivering this proven capability to the market, and this is another step forward as we sustain a range of clean, efficient solutions in transit."
BAE Systems and Cummins have worked together to develop hybrid electric solutions for buses since 1994. This newly expanded collaboration underscores a shared commitment to offering more emission-reducing options in transit.
Hybrid electric buses facilitate workforce development for training on high-voltage systems and do not require investment in extensive charging infrastructure.
In addition, hybrid buses with BAE Systems' electric drive systems allow for increased zero-emission capable solutions. This includes proven engine start and stop and geofencing technology, allowing a hybrid bus to automatically switch to full electric bus mode when entering designated green zones.
BAE Systems has more than 25 years of experience developing and integrating electric power and propulsion systems for buses, boats, and heavy-duty vehicles. The company has more than 16,000 propulsion systems in service on transit buses worldwide, including on hybrid electric, battery electric, and hydrogen fuel cell applications.
Its electric propulsion technology is developed and serviced at its facilities in Endicott, New York and Rochester, U.K.

'BAE Systems To Collaborate With Cummins On Transit Bus Hybrid Drivetrain For 2027 And Beyond'

Oral presentation will feature new data for investigational REGN7075, an EGFRxCD28 costimulatory bispecific with the potential to enhance the treatment of certain advanced solid tumors in combination with Libtayo&#xAE; (cemiplimab-rwlc) &nbsp;
17 presentations to highlight Regeneron's investigational pipeline including checkpoint inhibitors, CD3 bispecifics and CD28 costimulatory bispecifics
TARRYTOWN, N.Y., April 24, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) today announced new and updated data from its oncology and hematology pipeline will be shared across 17 presentations at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting, taking place from May 31 to June 5 in Chicago, IL. Notably, new safety and efficacy results from a Phase 1/2 trial investigating the costimulatory bispecific antibody REGN7075 (EGFRxCD28) in combination with Libtayo in patients with certain advanced solid tumors will be featured in an oral presentation.
"The breadth of our presentations at ASCO showcase our progress in advancing multiple promising and distinct investigational treatment approaches for a diverse array of difficult-to-treat cancers," said George D. Yancopoulos, M.D., Ph.D., Board co-Chair, President and Chief Scientific Officer at Regeneron. "These latest clinical results build on our ongoing commitment to cancer research and reflect our focus on advancing a pipeline of internally-developed candidates that have the potential to offer novel and differentiated therapies. Poised to tackle more than 30 types of cancer, our oncology pipeline is a testament to Regeneron's relentless commitment to transforming cancer care for those who need it most."
Beyond the REGN7075 data, additional presentations will feature results from Regeneron's diverse pipeline of checkpoint inhibitors and bispecific antibodies. Among them are presentations on updated data and new analyses for linvoseltamab (BCMAxCD3) in multiple myeloma; odronextamab (CD20xCD3) in several lymphoma subtypes; REGN6569 (GITR) in combination with Libtayo across solid tumors; and fianlimab (LAG-3 inhibitor) in combination with Libtayo in non-small cell lung cancer, melanoma and head and neck cancer.
Regeneron presentations at ASCO:&nbsp;
<figure class="table"> 
<table>
<tbody>
<tr>
<td>Medicine&nbsp;</td>
<td>Abstract title&nbsp;</td>
<td>Abstract&nbsp;</td>
<td>Lead author&nbsp;</td>
<td>Presentation date/time&nbsp; (all CDT)&nbsp;</td>
</tr>
<tr>
<td colspan="5">Solid Tumor Malignancies&nbsp;</td>
</tr>
<tr>
<td>REGN7075, Libtayo &nbsp;</td>
<td>A Phase 1/2 study of REGN7075 in combination with cemiplimab in patients with advanced solid tumors: Updated dose escalation results&nbsp;</td>
<td>#2503&nbsp; Oral Presentation&nbsp; Session— Developmental Therapeutics—Immunotherapy&nbsp;</td>
<td>Segal, N.H.&nbsp;</td>
<td>Monday, June 3&nbsp; 11:30 a.m. – 2:30 p.m.&nbsp;</td>
</tr>
<tr>
<td>REGN6569, Libtayo&nbsp; &nbsp;</td>
<td>A Phase 1 study of REGN6569, a GITR mAb, in combination with cemiplimab in patients (pts) with advanced solid tumor malignancies: Initial dose-escalation results&nbsp;</td>
<td>#2650&nbsp; Poster Presentation&nbsp; Session— Developmental Therapeutics—Immunotherapy&nbsp;</td>
<td>Lakhani, N.J.&nbsp;</td>
<td>Saturday, June 1&nbsp; 9:00 a.m. – 12:00 p.m.&nbsp;</td>
</tr>
<tr>
<td colspan="5">Blood Cancer&nbsp;</td>
</tr>
<tr>
<td>Linvoseltamab&nbsp;</td>
<td>Indirect comparison of linvoseltamab (linvo) versus teclistamab (tec) for treatment of triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM)&nbsp;&nbsp;&nbsp;</td>
<td>#7560&nbsp; Poster Presentation&nbsp; Session— Hematologic Malignancies—Plasma Cell Dyscrasia&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</td>
<td>Jagannath, S.&nbsp;</td>
<td>Monday, June 3&nbsp; 9:00 a.m. – 12:00 p.m.&nbsp;</td>
</tr>
<tr>
<td>Linvoseltamab&nbsp;</td>
<td>Comparative effectiveness of linvoseltamab (Linvo) vs. standard of care (SOC) in real-world patients (pts) with triple class exposed (TCE) relapsed/refractory multiple myeloma (RRMM)&nbsp;&nbsp;&nbsp;</td>
<td>#7561&nbsp; Poster Presentation&nbsp; Session— Hematologic Malignancies—Plasma Cell Dyscrasia&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</td>
<td>Kumar, S.&nbsp;</td>
<td>Monday, June 3&nbsp; 9:00 a.m. – 12:00 p.m.&nbsp;</td>
</tr>
<tr>
<td>Odronextamab&nbsp;</td>
<td>Phase 3 trial evaluating the efficacy and safety of odronextamab versus investigator's choice in previously untreated follicular lymphoma (OLYMPIA-1)&nbsp;&nbsp;&nbsp;</td>
<td>#7096&nbsp; Poster Presentation&nbsp; Session— Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia&nbsp; &nbsp;</td>
<td>Birhiray, R.&nbsp;</td>
<td>Monday, June 3&nbsp; 9:00 a.m. – 12:00 p.m.&nbsp;</td>
</tr>
<tr>
<td>Odronextamab&nbsp;</td>
<td>Phase 3 trial evaluating the efficacy and safety of odronextamab plus chemotherapy versus rituximab plus chemotherapy in previously untreated follicular lymphoma (OLYMPIA-2)&nbsp;</td>
<td>#7099&nbsp; Poster Presentation&nbsp; Session— Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia&nbsp; &nbsp;</td>
<td>Hardin, C.&nbsp;</td>
<td>Monday, June 3&nbsp; 9:00 a.m. – 12:00 p.m.&nbsp;</td>
</tr>
<tr>
<td>Odronextamab &nbsp;</td>
<td>Phase 3 trial evaluating efficacy and safety of odronextamab plus CHOP vs rituximab plus CHOP in previously untreated diffuse large B-cell lymphoma (DLBCL; OLYMPIA-3)&nbsp;</td>
<td>#7086 Poster Presentation&nbsp; Session— Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia&nbsp; &nbsp;</td>
<td>Matasar, M.&nbsp;</td>
<td>Monday, June 3&nbsp; 9:00 a.m. – 12:00 p.m.&nbsp;</td>
</tr>
<tr>
<td>Odronextamab&nbsp;</td>
<td>Phase 3 trial evaluating the efficacy and safety of odronextamab versus standard-of-care (SOC) therapy in relapsed/refractory (R/R) aggressive B-cell non-Hodgkin lymphoma (B-NHL;OLYMPIA-4)&nbsp;</td>
<td>#7093&nbsp; Poster Presentation&nbsp; Session— Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia&nbsp;</td>
<td>Hawkes, E.A.&nbsp;</td>
<td>Monday, June 3&nbsp; 9:00 a.m. – 12:00 p.m.&nbsp;</td>
</tr>
<tr>
<td>Odronextamab &nbsp;</td>
<td>Phase 3 trial of odronextamab plus lenalidomide versus rituximab plus lenalidomide in relapsed/refractory (R/R) follicular lymphoma (FL) and marginal one lymphoma (MZL; (OLYMPIA-5)&nbsp;</td>
<td>#7094&nbsp; Poster Presentation&nbsp; Session— Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia&nbsp;</td>
<td>Vitolo, U.</td>
<td>Monday, June 3&nbsp; 9:00 a.m. – 12:00 p.m.&nbsp;</td>
</tr>
<tr>
<td>Odronextamab&nbsp;</td>
<td>Results from the follicular lymphoma (FL) outcomes in relapsed/refractory (R/R) patients treated with systemic therapy in a real-world assessment (FLORA) study&nbsp;&nbsp;&nbsp;</td>
<td>#7076&nbsp; Poster Presentation&nbsp; Session— Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia&nbsp;</td>
<td>Luminari, S.&nbsp;</td>
<td>Monday, June 3&nbsp; 9:00 a.m. – 12:00 p.m.&nbsp;</td>
</tr>
<tr>
<td colspan="5">Skin Cancer&nbsp;</td>
</tr>
<tr>
<td>Fianlimab, Libtayo&nbsp;</td>
<td>A Phase 3 trial of fixed dose combinations of fianlimab (anti-LAG-3) + cemiplimab (anti-PD-1) versus relatlimab + nivolumab in patients with unresectable or metastatic melanoma&nbsp;</td>
<td>#TPS9611&nbsp; Poster Presentation&nbsp; Session— Melanoma/Skin Cancers&nbsp;</td>
<td>Khushalani, N.I.&nbsp;</td>
<td>Saturday, June 1&nbsp; 1:30 p.m. – 4:30 p.m.&nbsp;</td>
</tr>
<tr>
<td colspan="5">Lung Cancer&nbsp;</td>
</tr>
<tr>
<td>Fianlimab, Libtayo</td>
<td>A Phase 2/3 study of fianlimab, cemiplimab, plus chemotherapy versus cemiplimab plus chemotherapy in first-line advanced non-small cell lung cancer&nbsp;&nbsp;&nbsp;</td>
<td>#TPS8660&nbsp; Poster Presentation&nbsp; Session— Lung Cancer—Non-Small Cell Metastatic&nbsp;</td>
<td>Gabrail, N.&nbsp;</td>
<td>Monday, June 3&nbsp; 1:30 p.m. – 4:30 p.m&nbsp;&nbsp;</td>
</tr>
<tr>
<td>Fianlimab, Libtayo&nbsp;</td>
<td>A Phase 2/3 study of fianlimab plus cemiplimab versus cemiplimab in patients with advanced non-small cell lung cancer with tumors expressing PD-L ≥50%&nbsp;</td>
<td>#TPS8663&nbsp; Poster Presentation&nbsp; Session— Lung Cancer—Non-Small Cell Metastatic&nbsp;</td>
<td>Faulkner, N.&nbsp;</td>
<td>Monday, June 3&nbsp; 1:30 p.m. – 4:30 p.m.&nbsp; &nbsp;</td>
</tr>
<tr>
<td colspan="5">Gynecologic Cancer&nbsp;&nbsp;</td>
</tr>
<tr>
<td>Libtayo&nbsp;</td>
<td>Combination of cemiplimab and ISA101b vaccine for the treatment of recurrent/metastatic HPV16 cervical cancer&#x2A;&nbsp;</td>
<td>#5522&nbsp; Poster Presentation&nbsp; Session— Gynecologic Cancer&nbsp;&nbsp;</td>
<td>Lorusso, D.&nbsp;</td>
<td>Monday, June 3&nbsp; 9:00 a.m. – 12:00 p.m.&nbsp;</td>
</tr>
<tr>
<td>Ubamatamab, Libtayo&nbsp;</td>
<td>A Phase 1/2 study of ubamatamab (REGN4018), a MUC16×CD3 bispecific antibody, administered alone or in combination with cemiplimab (anti–PD-1) in patients with recurrent ovarian cancer or MUC16+ endometrial cancer: Trial in progress update&nbsp;</td>
<td>#TPS5632&nbsp; Poster Presentation&nbsp; Session— Gynecologic Cancer&nbsp;</td>
<td>Nieuwenhuysen, E.&nbsp;</td>
<td>Monday, June 3&nbsp; 9:00 a.m. – 12:00 p.m.&nbsp;</td>
</tr>
<tr>
<td colspan="5">Head and Neck Cancer&nbsp;</td>
</tr>
<tr>
<td>Fianlimab, Libtayo</td>
<td>A Phase 1 study of fianlimab (anti-LAG-3) in combination with cemiplimab (anti-PD-1) in patients with advanced HNSCC&nbsp;</td>
<td>#6038&nbsp; Poster Presentation&nbsp; Session— Head and Neck Cancer&nbsp;</td>
<td>Cho, B.C.&nbsp;</td>
<td>Sunday, June 2&nbsp; 9:00 a.m. – 12:00 p.m.&nbsp;</td>
</tr>
<tr>
<td>DB-020&nbsp;</td>
<td>A phase 1 clinical trial of DB-020 intratympanic injections administered prior to high dose cisplatin chemotherapy to reduce ototoxicity&nbsp;</td>
<td>#6100 Poster Presentation&nbsp; Session— Head and Neck Cancer&nbsp;</td>
<td>Rischin, D.&nbsp;</td>
<td>Sunday, June 2&nbsp; 9:00 a.m. – 12:00 p.m.&nbsp;</td>
</tr>
</tbody>
</table>
</figure>
&#x2A;Study conducted in collaboration between Regeneron and ISA.
The potential uses of Libtayo, REGN7075, odronextamab, linvoseltamab, REGN6569, fianlimab and DB-020 as described above are investigational, and their safety and efficacy in these uses have not been fully evaluated by any regulatory authority. REGN7075, odronextamab, linvoseltamab, REGN6569, fianlimab and DB-020 are not currently approved for use in any indication.&nbsp;

REGN

Regeneron To Showcase Progress In Advancing Novel Investigational Treatment Approaches For A Broad Range Of Solid Tumors And Blood Cancers At ASCO

B. Riley Financial, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RILY#NASDAQ">RILY</a>) shares are trading higher Wednesday after the company announced the results of an independent investigation showed the company and its executives had no involvement with, or knowledge of, any of the alleged misconduct <a href="https://www.benzinga.com/pressreleases/24/04/n38399032/b-riley-financial-files-2023-annual-report-on-form-10-k">concerning Brian Kahn or any of his affiliates.</a>
The Details:
B. Riley engaged Winston &amp; Strawn LLP as independent counsel to assist the Audit Committee in conducting an investigation of the historical relationship between the company and Brian Kahn, as well as certain related allegations asserted against the company by certain short sellers.
The company also noted the independent investigation was conducted subsequent to the company&#8217;s February 22 disclosure of the internal review performed with the assistance of Sullivan &amp; Cromwell LLP as outside counsel.
B. Riley shares are moving on heavy trading volume with more than fives times the stock's average volume already traded in Wednesday's session. According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, 67.17% of available shares are being sold short which can contribute to large price moves when combined with heavy trading volume.&nbsp;
Related News: <a href="https://www.benzinga.com/news/24/04/38360358/whats-going-on-with-luxury-ev-maker-lucids-stock">What&#8217;s Going On With Luxury EV-Maker Lucid&#8217;s Stock?</a>
<h2 class="wp-block-heading">Is RILY A Good Stock To Buy?</h2>
An investor can make a few decisions when deciding whether a stock is a good buy. In addition to valuation metrics and price action which you can find on Benzinga's quote pages &#8211; like <a href='https://www.benzinga.com/quote/RILY'>B. Riley Financial</a>&#8216;s page for example &#8211; there are factors like whether or not a company pays a dividend or buys a large portion of its stock each quarter.
These are known as capital allocation programs. B. Riley Financial does pay a dividend, which yields 10.68% per year as of the closing price on April 24. Feel free to search Benzinga's <a href="https://www.benzinga.com/calendars/dividends">dividend calendar</a> for the next company that is due to pay a dividend and determine what kind of yield you can earn for holding a share of the company.
Buyback programs are obviously different and highly variable. A company can approve a buyback program and purchase shares as it sees fit over the course of time in which the buyback was authorized. Looking through the latest news on <a href="https://www.benzinga.com/quote/RILY">B. Riley Financial</a> will often yield whether or not the company has approved a buyback program recently. Buyback programs usually serve as a support for share prices, serving as a backstop for demand.
RILY Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, B. Riley Financial shares are up 40.8% at $30.59 at the time of publication Wednesday.
Image: Pete Linforth from Pixabay

RILY

Why B. Riley Financial Stock Is Up Today

<ul>
<li>Oral presentation at&nbsp;ASCO 2024 scheduled for Monday, June 3, 2024, at 9:51 AM CDT</li>
<li>The abstract summary will be available on Thursday, May 23, 2024 at ~5:00pm ET</li>
</ul>
SOUTH SAN FRANCISCO, Calif., April 24, 2024 /PRNewswire/ --&nbsp;IDEAYA Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDYA#NASDAQ">IDYA</a>), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that interim results from the investigator-sponsored Phase 2 trial evaluating darovasertib safety and efficacy as neoadjuvant/adjuvant treatment in uveal melanoma (UM) have been selected for an oral presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 31-June 4, 2024 in Chicago, Illinois.
Details for the oral presentation are as follows:
Session: Melanoma/ Skin Cancers
Title: A Phase 2 Safety and Efficacy Study of Neoadjuvant/Adjuvant Darovasertib for Localized Ocular Melanoma
Presenter: Anthony Joshua, M.B.B.S, Ph.D., FRACP
Abstract number: 9510
Date and Time: June 3, 2024, at 9:51 AM CDT
ASCO will publish the abstract summary on Thursday, May 23, 2024, at approximately 5:00 pm ET.

IDYA

IDEAYA Biosciences Announces ASCO 2024 Oral Presentation For Darovasertib In Neoadjuvant Uveal Melanoma Phase 2 Investigator Sponsored Study

WIIM

Norfolk Southern shares are trading lower following worse-than-expected Q1 financial results.

Company to present an update of its ongoing monotherapy and combination Phase 1/1b study of WTX-124 in advanced or metastatic solid tumors &nbsp;
WATERTOWN, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the "Company" or "Werewolf") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOWL#NASDAQ">HOWL</a>), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer, today announced that an abstract providing an update of the Company's ongoing monotherapy and combination Phase 1/1b study of WTX-124, its interleukin 2 (IL-2) INDUKINE&#x2122; molecule, has been accepted for poster presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 31 - June 4 in Chicago, Illinois.
Details for the poster presentation are as follows:
Title: A phase 1/1b study of the IL-2 prodrug WTX-124 in patients with locally advanced or metastatic solid tumors after checkpoint inhibitor therapy: Initial results of the combination dose escalation with pembrolizumab Session Date: Saturday, June 1, 2024 Session Time:&nbsp;9:00 AM-12:00 PM CDT Board Number: 102

HOWL

Werewolf Therapeutics Announces WTX-124 Clinical Abstract Accepted For Presentation At The 2024 ASCO Annual Meeting

GE Aerospace shares are trading lower. The stock gained Tuesday following Q1 financial results.

General Dynamics shares are trading lower following worse-than-expected Q1 financial results.

CG Oncology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGON#NASDAQ">CGON</a>), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced that an abstract with final results of CORE-001, its Phase 2 trial of cretostimogene in combination with pembrolizumab, will be presented at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting, which will take place from May 31-June 4, 2024, at McCormick Place Convention Center, in Chicago, IL. &nbsp;
"We are delighted to be sharing the final results from our CORE-001 Phase 2 trial at ASCO, in line with the guidance we previously gave of providing additional CORE-001 durability data in 1H 2024," said Vijay Kasturi, M.D., Chief Medical Officer, CG Oncology. "In anticipation of sharing the final results from this trial, we would like to extend our heartfelt thanks to the investigators and patients who contributed to the trial's success."
Details of the abstract are as follows:
Final results of CORE-001 trial of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in Patients with BCG-Unresponsive, Non-Muscle Invasive Bladder Cancer with Carcinoma in Situ Abstract Number: 4601 Session &amp; Primary Track: Poster Session, Genitourinary Cancer - Kidney and Bladder Presenter: Roger Li, M.D., lead study investigator and Urologic Oncologist at Moffitt Cancer Center Presentation Date &amp; Time: June 2, 2024, 9:00-10:00am Central Daylight Time Location: McCormick Place Convention Center, Hall A

CGON

CG Oncology To Unveil Results On Cretostimogene In Combination With Pembrolizumab At ASCO 2024

New Oriental Education &amp; Technology Group, Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EDU#NYSE">EDU</a>) shares are trading lower on Wednesday.
The company reported that in the third quarter, adjusted earnings per share was 63 cents,<a target="_blank" href="https://www.benzinga.com/pressreleases/24/04/n38397942/new-oriental-announces-results-for-the-third-fiscal-quarter-ended-february-29-2024" rel="noreferrer noopener">&nbsp;missing the street view of 79 cents.&nbsp;</a>
Quarterly revenues of $1.207 billion&nbsp;beat the street view of $1.105 billion. Total net revenues increased by 60.1%&nbsp;year over year, owing&nbsp;to educational new business initiatives, East Buy private label products, and&nbsp;livestreaming&nbsp;e-commerce business.
Operating income increased by 70.6%&nbsp;year over year&nbsp;to&nbsp;$113.4 million&nbsp;for the third&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">fiscal quarter of 2024.</a>
Net income attributable to New Oriental increased by 6.8%&nbsp;year over year&nbsp;to&nbsp;$87.2 million.
&#8220;Our overseas test preparation and overseas study consulting businesses maintained a strong upward trajectory, exhibiting approximately 52.6% and 25.7% growth year over year, respectively,&#8221; said Michael Yu, New Oriental&#8217;s Executive Chairman.
The total number of schools and learning centers was 911 as of&nbsp;February-end, an increase of 68 and 199 compared to 843 as of&nbsp;November 30, 2023,&nbsp;and 712 as of&nbsp;February 28, 2023, respectively. &#8220;Among these new educational business initiatives, our non-academic tutoring courses were offered in around 60 cities, attracting approximately 355,000 student enrollments in this fiscal quarter,&#8221; Yu added.
Outlook: New Oriental expects total net revenues in the fourth quarter of&nbsp;$1.101 billion-$1.127 billion (estimate: $1.1 billion), representing a year-over-year&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">increase&nbsp;in the range&nbsp;of 28%-31%.</a>
The projected&nbsp;increase of revenue&nbsp;in the functional currency&nbsp;Renminbi&nbsp;is&nbsp;expected&nbsp;to be&nbsp;34% to 37% for the fourth quarter of the fiscal year 2024.
Price Action: EDU shares are trading lower by 17.1% to $74.27 at last check Wednesday.
Image: Shutterstock/ MD Duran

Education

New Oriental Education & Technology Group

What's Going On With New Oriental Education Shares Today?

Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) moved higher, with the cryptocurrency prices trading above the key $66,000 level on Wednesday.
Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) also recorded gains, trading above the key $3,200 mark this morning.
Hedera (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/hbar/usd">HBAR</a>) was the top gainer over the prior 24 hours, while Akash Network (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">AKT</a>) turned out to be the biggest loser.
At the time of writing, the global crypto market cap rose to $2.46 trillion, recording a 24-hour gain of 1%. BTC was trading higher by 0.4% at $66,392 while ETH rose by around 2.9% to $3,266 on Wednesday.
Here are the top ten crypto gainers and losers over the past 24 hours:
<h3 class="wp-block-heading">Gainers&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</h3>
Hedera (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/hbar/usd">HBAR</a>)
Price: $0.1285
24-hour gain: 46.3%
Bonk (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">BONK</a>)
Price: $0.00002767
24-hour gain: 36.5%
dogwifhat (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">WIF</a>)
Price: $3.42
24-hour gain: 20%
Algorand (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/algo/usd">ALGO</a>)
Price: $0.2287
24-hour gain: 19%
Pepe (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">PEPE</a>)
Price: $0.000007906
24-hour gain: 15.2%
<h3 class="wp-block-heading">Losers</h3>
Akash Network (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">AKT</a>)
Price: $5.09
24-hour drop: 19.6%
Gnosis (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">GNO</a>)
Price: $367.48
24-hour drop: 7%
Neo (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/neo/usd">NEO</a>)
Price: $18.51&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
24-hour drop: 5.6%
Cardano (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/ada/usd">ADA</a>)
Price: $0.4954
24-hour drop: 4.3%
Stacks (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/stx/usd">STX</a>)
Price: $2.87
24-hour drop: 4.1%
Check This Out: <a href="https://www.benzinga.com/news/earnings/24/04/38396305/tesla-boeing-and-3-stocks-to-watch-heading-into-wednesday">Tesla, Boeing And 3 Stocks To Watch Heading Into Wednesday</a>

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Intraday Update

$ADA

$AKT

$ALGO

$BONK

$BTC

$ETH

$GNO

$HBAR

$NEO

$PEPE

$STX

$WIF

Ethereum Surpasses $3,200; Hedera Emerges As Top Gainer

Notable earnings before Thursday's open

Vericel Q4 2023 Earnings Preview

Vericel GAAP EPS of $0.26 beats by $0.09, revenue of $65M beats by $1.05M

Vericel Corporation (VCEL) Q4 2023 Earnings Call Transcript

Vericel Corporation 2023 Q4 - Results - Earnings Call Presentation

Vericel (VCEL – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Swayampakula Ramakanth from ...

Buy Rating Affirmed for Vericel on Strong Financials and Growth Prospects

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Vericel (VCEL – Research Report), Tenet Healthcare...

Analysts Conflicted on These Healthcare Names: Vericel (VCEL), Tenet Healthcare (THC) and Veeva Systems (VEEV)

Biotech is in a bull market aș measured by 2023 trends with a double testing of lows on 11/23.

It's A Bull Market But Harder To Pick Small Cap Biotech Winners Because Of Volatility

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Viridian Therapeutics (VRDN – Research Report), Omni...

Analysts Offer Insights on Healthcare Companies: Viridian Therapeutics (VRDN), OmniAb (OABI) and Vericel (VCEL)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Vor Biopharma (VOR – Research Report), Inotiv (NOTV ...

Analysts Offer Insights on Healthcare Companies: Vor Biopharma (VOR), Inotiv (NOTV) and Vericel (VCEL)

ABEV

ABUS

ACIW

ACLLF

AMRN

ANIP

ARGX

BBWI

CCOI

CDUAF

CELH

CMRX

COMM

CRBU

CRON

CRSP

CVEO

DAVA

DOLE

ENIC

EVRG

EVRI

EXLS

FREY

GDRX

GECC

GLNG

GOLF

HOLX

HYFM

ICAGY

IHRT

INSW

IPWR

ITRN

KPTI

MLCO

MPLN

NOMD

NOTV

NREF

NTES

NVRI

OABI

OLPX

OPRA

PCRX

PSNY

PZZA

QDEL

STRA

TCNNF

TCPC

TGNA

TTSH

UNIT

VEEV

VEOEY

VERX

VRDN

VRNA

VRNOF

XFLT

XMTR

XRAY

Press Releases

Vericel to Report Third-Quarter 2023 Financial Results on November 8, 2023

Vericel to Present at the Stephens Annual Investment Conference

Vericel Reports Third Quarter 2023 Financial Results and Raises Full-Year 2023 Financial Guidance

Vericel to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024

Vericel Announces Preliminary Full-Year and Fourth Quarter 2023 Financial Results

Vericel to Present at the Canaccord Genuity Musculoskeletal Conference on Monday, February 12, 2024

Vericel to Report Fourth-Quarter and Full-Year 2023 Financial Results on February 29, 2024

Vericel to Present at the TD Cowen 44th Annual Health Care Conference on Tuesday, March 5, 2024

Vericel Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Full-Year 2024 Financial Guidance